MarketCapExport financials
Interpace Biosciences (IDXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Interpace Biosciences Balance Sheet 2025-2009 | IDXG
Brief overview of Interpace Biosciences's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
The asset base decreased -11.9%, from $38.4 million to $33.8 million. Resources became smaller over the five periods.
Liabilities increased less than assets, posting -66.6% versus -11.9%. That relationship usually strengthens the balance sheet.
Equity funds 66.1% of assets versus -110.4% initially. This creates a conservative balance sheet structure.
The period ended with net cash: net debt stood at -$1.3 million. This supports financial flexibility.
The cash reserve occupies 7.4% of the balance sheet, previously 7%. It is one marker of short-term resilience.
Retained earnings remain negative at -$210.8 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
Interpace Biosciences's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-1.32 M | 105 K | -1.65 M | -2.4 M | -1.39 M | 1.97 M | 4.78 M | -6.07 M | -15.2 M | 7.31 M | 87 K | 4.15 M | -45.6 M | -52.8 M | -64.3 M | - | - |
Long Term Debt |
752 K | 1.18 M | 1.47 M | 1.85 M | 520 K | - | 3 M | - | - | 7.91 M | 7.23 M | 27.2 M | - | - | - | - | - |
Long Term Debt Current |
431 K | 383 K | 377 K | 578 K | 762 K | 1.03 M | - | - | - | - | 1.16 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 10 M | 38.7 M | 7.01 M | 5.64 M | 19 M | 31.3 M | 62.2 M | 5.18 M | 6.43 M | 7.78 M | - | - |
Total Current Liabilities |
5.1 M | 10.6 M | 11.4 M | 14.3 M | 15.7 M | 18.2 M | 17.3 M | 8.49 M | 8.09 M | 16.2 M | 23.4 M | 33.6 M | 31.4 M | 36.4 M | 46.1 M | 43.3 M | - |
Total Liabilities |
11.5 M | 17 M | 22.1 M | 32.5 M | 34.3 M | 28.2 M | 56 M | 15.5 M | 13.7 M | 35.2 M | 54.7 M | 95.8 M | 36.6 M | 42.8 M | 53.9 M | 54.9 M | - |
Deferred Revenue |
- | - | - | - | - | 54 K | 457 K | - | - | - | - | 6.75 M | 9.38 M | 14.5 M | 15.9 M | 13.4 M | - |
Retained Earnings |
-211 M | -235 M | -242 M | -249 M | -227 M | -212 M | -168 M | -141 M | -132 M | -120 M | -111 M | -99.9 M | -83.8 M | -79.3 M | -53.7 M | -41.8 M | - |
Total Assets |
33.8 M | 14.8 M | 13.1 M | 16 M | 38.4 M | 45.7 M | 69.1 M | 48.4 M | 53.6 M | 41.8 M | 67.7 M | 116 M | 69.1 M | 78.4 M | 113 M | 124 M | - |
Cash and Cash Equivalents |
2.5 M | 1.46 M | 3.5 M | 4.83 M | 2.67 M | 2.77 M | 2.32 M | 6.07 M | 15.2 M | 602 K | 8.31 M | 23.1 M | 45.6 M | 52.8 M | 64.3 M | 62.7 M | 72.5 M |
Book Value |
22.4 M | -2.22 M | -9 M | -16.5 M | 4.12 M | 17.5 M | 13 M | 32.9 M | 39.9 M | 6.53 M | 13 M | 20.1 M | 32.5 M | 35.6 M | 59.5 M | 69.5 M | - |
Total Shareholders Equity |
22.4 M | -2.22 M | -55.5 M | -58.1 M | -42.4 M | -29.1 M | -4.48 M | 15.4 M | 39.9 M | 39.9 M | 13 M | 20.1 M | 32.5 M | 35.6 M | 59.5 M | 69.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Interpace Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
752 K | 635 K | 1.18 M | 864 K | 974 K | 1.08 M | 1.18 M | 1.19 M | 1.29 M | 1.36 M | 1.47 M | 1.56 M | 1.65 M | 1.75 M | 1.85 M | 184 K | 2.72 M | 2.97 M | 520 K | 3.23 M | 3.2 M | 3.44 M | 3.68 M | 3.78 M | 3.68 M | 1.47 M | 2.71 M | 2.96 M | 2.59 M | 2.59 M | - | - | - | - | - | - | - | 4.36 M | 7.91 M | 7.91 M | 7.91 M | 7.91 M | 7.23 M | 7.23 M | 7.23 M | 7.23 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.56 M | 4.57 M | - | - | 4.25 M | 4.32 M | 4.73 M | 4.34 M | 4.32 M | 4.29 M | 4.29 M | 4.29 M | 4.29 M | - | - | 4.71 M | 4.7 M | 6.18 M | 8.08 M | 8.74 M | 6.18 M | 8.81 M | 9.14 M | 9.14 M | 9.14 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 6.43 M | 6.43 M | 6.43 M | 6.43 M | 7.78 M | 7.78 M | 7.78 M | 7.78 M |
Total Liabilities |
11.5 M | 10.3 M | 17 M | 12.3 M | 13.5 M | 15.1 M | 17 M | 25.2 M | 25.5 M | 26.7 M | 28.2 M | 30.4 M | 31.6 M | 31.9 M | 32.5 M | 30.4 M | 36.9 M | 36.2 M | 34.3 M | 32.4 M | 32.4 M | 30.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 15.7 M | 15.5 M | 15.5 M | 15.5 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 54.7 M | 54.7 M | 54.7 M | 54.7 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | 42.8 M | 42.8 M | 42.8 M | 42.8 M | 53.9 M | 53.9 M | 53.9 M | 53.9 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18 K | 31 K | 40 K | 40 K | 43 K | 52 K | 54 K | 54 K | 54 K | 54 K | 457 K | 457 K | 457 K | 457 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.11 M | 6.87 M | 10.9 M | 6.75 M | 7.61 M | 6.75 M | 6.75 M | 7.35 M | 9.38 M | 9.38 M | 9.38 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M |
Retained Earnings |
-211 M | -210 M | -235 M | -233 M | -234 M | -234 M | -235 M | -244 M | -246 M | -248 M | -248 M | -249 M | -248 M | -249 M | -249 M | -247 M | -233 M | -229 M | -227 M | -223 M | -220 M | -216 M | -212 M | -212 M | -212 M | -212 M | -186 M | -186 M | -186 M | -186 M | -159 M | -141 M | -141 M | -141 M | -132 M | -132 M | -132 M | -132 M | -120 M | -120 M | -120 M | -120 M | -111 M | -111 M | -111 M | -111 M | -99.9 M | -99.9 M | -99.9 M | -99.9 M | -83.8 M | -83.8 M | -83.8 M | -83.8 M | -79.3 M | -79.3 M | -79.3 M | -79.3 M | -53.7 M | -53.7 M | -53.7 M | -53.7 M |
Total Assets |
33.8 M | 33.4 M | 14.8 M | 12 M | 12.3 M | 14.5 M | 14.8 M | 14 M | 13 M | 12.1 M | 13 M | 14.2 M | 15.9 M | 15.9 M | 16 M | 15.3 M | 35.5 M | 38.4 M | 38.4 M | 40.3 M | 43.2 M | 43.9 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 31.1 M | 48.4 M | 48.4 M | 48.4 M | 36.6 M | 53.6 M | 53.6 M | 53.6 M | 25.1 M | 41.8 M | 41.8 M | 41.8 M | 64.7 M | 67.7 M | 67.7 M | 67.7 M | 115 M | 116 M | 116 M | 116 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 78.4 M | 78.4 M | 78.4 M | 78.4 M | 113 M | 113 M | 113 M | 113 M |
Cash and Cash Equivalents |
1.46 M | 2.65 M | 3.5 M | 1.42 M | 502 K | 1.2 M | 1.46 M | 1.4 M | 500 K | 2.81 M | 3.5 M | 5.03 M | 5.08 M | 5.6 M | 4.83 M | 6.31 M | 2.12 M | 3.1 M | 2.67 M | 3.43 M | 3.79 M | 2.84 M | 2.77 M | 2.77 M | 2.77 M | 2.77 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | 6.07 M | 6.07 M | 6.07 M | 6.07 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 602 K | 602 K | 602 K | 602 K | 8.31 M | 8.31 M | 8.31 M | 8.31 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 64.3 M | 64.3 M | 64.3 M | 64.3 M |
Book Value |
22.4 M | 23.1 M | -2.22 M | -298 K | -1.21 M | -582 K | -2.22 M | -11.1 M | -12.5 M | -14.6 M | -15.1 M | -16.1 M | -15.7 M | -16 M | -16.5 M | -15.1 M | -1.42 M | 2.2 M | 4.12 M | 7.89 M | 10.7 M | 13.6 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 15.4 M | 32.9 M | 32.9 M | 32.9 M | 22.9 M | 39.9 M | 39.9 M | 39.9 M | -10.1 M | 6.53 M | 6.53 M | 6.53 M | 10.1 M | 13 M | 13 M | 13 M | 19.4 M | 20.1 M | 20.1 M | 20.1 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 59.5 M | 59.5 M | 59.5 M | 59.5 M |
Total Shareholders Equity |
-2.22 M | 23.1 M | -55.5 M | -298 K | -1.21 M | -582 K | -2.22 M | -50.5 M | -52.3 M | -54.8 M | -61.7 M | -62.7 M | -62.2 M | -62.5 M | -63.1 M | -61.6 M | -48 M | -44.3 M | -42.4 M | -38.6 M | -35.8 M | -32.9 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -4.48 M | -4.48 M | -4.48 M | -4.48 M | 15.4 M | 32.9 M | 32.9 M | 32.9 M | 22.9 M | 39.9 M | 39.9 M | 39.9 M | -10.1 M | 6.53 M | 6.53 M | 6.53 M | 10.1 M | 13 M | 13 M | 13 M | 19.4 M | 20.1 M | 20.1 M | 20.1 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 59.5 M | 59.5 M | 59.5 M | 59.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Interpace Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
$ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
$ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
$ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
$ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
$ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
$ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
$ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
$ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
$ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
$ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
$ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
$ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
$ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
$ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
$ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
$ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
$ 78.47 | 2.8 % | $ 4.18 B | USA |